Arvinas (ARVN) vs Evolus (EOLS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Evolus (EOLS) has outperformed Arvinas (ARVN) over the past year, losing 4.8% versus a loss of 43.9%. Over five years, EOLS leads with a +14.4% price change compared with -91.8% for ARVN. Evolus is the larger company by market cap ($431.5 million vs $423.0 million), about 1.0 times the size.
Evolus converts more of its revenue into profit, with a net margin of -17.4% versus -30.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | EOLS |
|---|---|---|
| Share price | $6.46 | $6.52 |
| Market cap | $423.03M | $431.55M |
| 1-day change | -4.15% | -6.86% |
| YTD return | -45.53% | -1.95% |
| 1-year return | -43.92% | -4.82% |
| 5-year return | -91.75% | +14.39% |
| Forward P/E | — | 22.68 |
| EPS (TTM) | $-0.08 | $-0.48 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $262.60M | $297.18M |
| Revenue growth (YoY) | -0.30% | +11.61% |
| Net income (latest FY) | $-80.80M | $-51.64M |
| Gross margin | — | 66.33% |
| Operating margin | -45.13% | -10.99% |
| Net margin | -30.77% | -17.38% |
| 52-week high | $14.51 | $9.31 |
| 52-week low | $6.33 | $3.86 |
| Distance from 52-week high | -55.48% | -29.97% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +116.72% | +136.20% |
| Average volume | 848.52K | 925.77K |
| Shares outstanding | 65.49M | 66.19M |
| Employees | 246 | 365 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- EOLS has outperformed ARVN by 39.1 percentage points over the past year.
- Evolus is more profitable, keeping -17.4 cents of every revenue dollar as net income versus -30.8 cents for Arvinas.
- Evolus grew revenue faster in its latest fiscal year (+11.61% vs -0.30%).
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
About Evolus
EOLS stock →Evolus, Inc., a performance beauty company, delivers products in the cash-pay aesthetic market in the United States, Canada, Europe, and Australia. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Evolysse, a collection of injectable hyaluronic acid gels, which includes various products, such as mid face, nasolabial folds, lips and eyes.
Health Care · Biotechnology: Pharmaceutical Preparations · 365 employees
ARVN vs EOLS FAQ
Which is bigger, Arvinas or Evolus?
Evolus (EOLS) is larger, with a market capitalization of $431.55M compared with $423.03M for Arvinas (ARVN).
Which stock has performed better over the past year, ARVN or EOLS?
EOLS returned -4.82% over the past 12 months, compared with -43.92% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Are Arvinas and Evolus in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.